- Esketamine, sold
under the
brand names Spravato (for depression) and
Ketanest (for anesthesia)
among others, is the S(+)
enantiomer of ketamine. It is...
-
allosteric modulator –
approved for
postpartum depression Esketamine (
Spravato) – non-competitive NMDA
receptor antagonist,
other actions Gepirone (Exxua)...
-
Archived from the
original on 2 July 2022.
Retrieved 18
January 2021. "
Spravato (esketamine)".
European Medicines Agency. 8 July 2022.
Archived from the...
- On 5
March 2019, the Food and Drug
Administration approved Janssen's
Spravato (esketamine
nasal spray) for treatment-resistant
major depressive disorder...
-
esketamine for the
treatment of
severe depression,
which is
marketed as
Spravato by
Janssen Pharmaceuticals. In 2019,
Johnson &
Johnson announced the release...
-
Chloroform Cyclopropane Desflurane Diethyl ether Enflurane Esketamine (
Spravato, Ketanest)
Ethyl chloride Etomidate (Amidate)
Isoflurane (Forane) Halothane...
-
Administration (FDA)
first approved the use of
intranasal esketamine (
Spravato)—an
enantiomer of ketamine—for the use of ketamine-derived
therapy for...
- off-label to
treat insomnia Sonata (zaleplon) – a non-benzodiazepine
hypnotic Spravato (esketamine) – a rapid-acting
antidepressant of the NMDA
receptor antagonist...
- S2CID 232262694. Bahr R,
Lopez A, Rey JA (June 2019). "Intranasal
Esketamine (
SpravatoTM) for Use in Treatment-Resistant
Depression In
Conjunction With an Oral...
-
SNRIs and NRIs with
various selective effects.
Esketamine (brand name
Spravato), the
first rapid-acting
antidepressant to be
approved for
clinical treatment...
